Skip to main content
Ab2674 #ACR24
➡️Most pts starting 1st-line TNFi, who didn't achieve treatment response at 3M, also didn't achieve re

Mrinalini Dey DrMiniDey

1 year 8 months ago
Ab2674 #ACR24 ➡️Most pts starting 1st-line TNFi, who didn't achieve treatment response at 3M, also didn't achieve response from months 3-12 ➡️1/4 pts achieving LDA/remission at 3M were no longer in LDA/remission at 12M @RheumNow https://t.co/pFOo86tJTx
Data from the RISE registry show that 9.3% of SLE pts had thrombocytopenia and a smaller percentage with mod-severe TP (

sheila RHEUMarampa

1 year 8 months ago
Data from the RISE registry show that 9.3% of SLE pts had thrombocytopenia and a smaller percentage with mod-severe TP (2.7%). Severe TP was much rare. Large data, but well represented grp? @RheumNow #ACR24 abs2680 https://t.co/Y1Lo9lJGtO
An early favorable response to TNFi initiation indicates better long-term success in RA. Assess early and adjust treatme

Jiha Lee JihaRheum

1 year 8 months ago
An early favorable response to TNFi initiation indicates better long-term success in RA. Assess early and adjust treatment accordingly. #ACR24 @RheumNow ABST#2674 https://t.co/YTThYiiLpZ
#ACR24 BEST Abstracts from Day 1

The RheumNow faculty have parked at the plenaries, trafficked the posters and have bee

Dr. John Cush RheumNow

1 year 8 months ago
#ACR24 BEST Abstracts from Day 1 The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day. https://t.co/FHu616Jpyq https://t.co/oKuRcGRRAZ
Would you trust #AI to carry out & read your #USS?

2 systems, ARTHUR & DIANA, were comparable to that of a rheu

Mrinalini Dey DrMiniDey

1 year 8 months ago
Would you trust #AI to carry out & read your #USS? 2 systems, ARTHUR & DIANA, were comparable to that of a rheumatologist specialising in MSK US at joint & patient levels Might this be the future of assessment in rheumatology care? AbL20 #ACR24 @RheumNow https://t.co/XtnlYafzp4
Nailfold video capillaroscopy (NVC) allows the definite distinction between primary and secondary #Raynaud's phenomenon

sheila RHEUMarampa

1 year 8 months ago
Nailfold video capillaroscopy (NVC) allows the definite distinction between primary and secondary #Raynaud's phenomenon and can identify early changes such as few giant capillaries &/or microhemorrages promoting early diagnosis @RheumNow #ACR24 @rheumarhyme https://t.co/Yl37w6BEZR
Another + #SLE #RCT - large N

#Dapirolizumab = Peg CD40L + SoC
Vs
#Placebo + SoC

Rapid improvemt
steroid sparing

S

Janet Pope Janetbirdope

1 year 8 months ago
Another + #SLE #RCT - large N #Dapirolizumab = Peg CD40L + SoC Vs #Placebo + SoC Rapid improvemt steroid sparing So what to use in Pts if +Ph3 👇 TYK2 Deucravacitinib JAKi Upadacitinib Dapirolizumab CAR 🚗 Rx Anifrolimumab Benlysta ETC! #ACRBest L16 @RheumNow #ACR24 https://t.co/wTFucF7BYO
Late breaking abstract L17
CAR-NK Therapy for Refractory SLE.
In a trial of 20 severe SLE patients:
- 75% achieved LLDAS

Antoni Chan MD (Prof) synovialjoints

1 year 8 months ago
Late breaking abstract L17 CAR-NK Therapy for Refractory SLE. In a trial of 20 severe SLE patients: - 75% achieved LLDAS, 50% achieved DORIS remission at 6 months - B cell reconstitution: 2–3 months post-treatment - Safety: 2 mild cytokine release syndrome with fever; no severe… https://t.co/MS8cutm48o
The combe-like pattern is observed in pts with APS and also in overlap syndrome
- presence of parallel microthrombi (ora

sheila RHEUMarampa

1 year 8 months ago
The combe-like pattern is observed in pts with APS and also in overlap syndrome - presence of parallel microthrombi (orange arrow) arranged perpendicularly, hence combe-like @RheumNow #ACR24 @rheumarhyme https://t.co/IjX7ld9lxW
The #scleroderma-like pattern on NVC is observed in pts with #dermatomyositis and MCTD
It consists of a combination of g

sheila RHEUMarampa

1 year 8 months ago
The #scleroderma-like pattern on NVC is observed in pts with #dermatomyositis and MCTD It consists of a combination of giant capillaries, some microhemorrhages, severe capillary loss and angiogenesis @RheumNow #ACR24 @rheumarhyme https://t.co/WO9BOYn4ir
In Vivo CAR T Cell Therapy.
A single intralymphatic injection of VivoVec™ particles:
- Generates functional CAR T cell

Antoni Chan MD (Prof) synovialjoints

1 year 8 months ago
In Vivo CAR T Cell Therapy. A single intralymphatic injection of VivoVec™ particles: - Generates functional CAR T cells in vivo - Achieves complete B cell depletion in NHPs without lymphodepletion - Demonstrates potential for an off-the-shelf solution for autoimmune disease… https://t.co/5DTzRvZjbY https://t.co/DvTOqnhn1V
Wt ⬇️ = Better #PROs in

👇autoimmune #rheumatic #diseases if > 5% wt loss.

#ACR24 ⁦@ACRheum⁩ ⁦@RheumN

Janet Pope Janetbirdope

1 year 8 months ago
Wt ⬇️ = Better #PROs in 👇autoimmune #rheumatic #diseases if > 5% wt loss. #ACR24 ⁦@ACRheum⁩ ⁦@RheumNow⁩ Didn’t work for non overwt Ex Normal BMI and T2DM 🤷 https://t.co/81OuTfZ0Nx
🚨 New SLE treatment update! 🚨 Dapirolizumab pegol (DZP), novel CD40L inhibitor, for moderate-to-severe lupus. Phas

Bella Mehta bella_mehta

1 year 8 months ago
🚨 New SLE treatment update! 🚨 Dapirolizumab pegol (DZP), novel CD40L inhibitor, for moderate-to-severe lupus. Phase 3 trial, DZP reduced disease activity, helped taper steroids, and achieved a higher BICLA Safe and generally well tolerated! #ACR24 #L16 @rheumnow https://t.co/lFrKjz4CZ1
In this study by Dr CArriens et al, there was no difference between the vaccine response to Influenza by either HAI or A

sheila RHEUMarampa

1 year 8 months ago
In this study by Dr CArriens et al, there was no difference between the vaccine response to Influenza by either HAI or Ab levels in Anifrolumab-treated pts. AEs - mild, moderate No serious aEs 💉#vaccinate your pts on anifrolumab with influenza @RheumNow #ACR24 abs2424 https://t.co/XPwlzUS02i
×